Actively Recruiting
Evaluating Sodium Bicarbonate Treatment for Adults Critically Ill with Metabolic Acidosis and Acute Kidney Injury to Reduce Kidney Complications
Led by Universität Münster · Updated on 2026-09-04
660
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether sodium bicarbonate can reduce major adverse kidney events by day 90 in critically ill adults with metabolic acidosis and acute kidney injury AKI. This condition greatly increases risks such as mortality and kidney failure. The study is a multicenter, double-blinded, randomized controlled trial designed to provide high-quality evidence for managing this serious condition. Participants are randomly assigned to receive either an intravenous infusion of 8.4% sodium bicarbonate or a balanced crystalloid placebo. The infusion follows a treatment algorithm targeting a blood pH greater than 7.30, starting at 100mlhr until specific pH and base excess targets are met, then reducing to 25mlhr. Treatment continues with dose adjustments to maintain the desired pH level. During the study, participants are monitored for kidney function, mortality, and the need for kidney replacement therapy over 90 days. Researchers collect blood tests, assess kidney health, and track major adverse kidney events including death, dialysis, or persistent kidney dysfunction. The trial aims to provide clear answers about sodium bicarbonates role in treating critically ill patients with AKI and metabolic acidosis.
CONDITIONS
Brief Title
Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury
Research Team
A
Alexander Zarbock, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here